Driving the evolution of therapies for chronic inflammatory disease.

Company Overview

Targeting the sources of chronic inflammatory diseases.

Our programs are designed to advance therapies for chronic inflammatory diseases in underserved patient populations where a high unmet need remains. We target these pathologies at the source with novel agents that exhibit best-in-class profiles for safety and efficacy, delivering therapeutics for patients that go beyond symptomatic relief.

Evommune brings together the right team, with the right experience, at the right time.
Chronic inflammation is increasingly recognized as an uncontrolled “pandemic,” acting as a common factor in the current erosion of life expectancy.1 Worldwide, 3 of 5 people die from some form of chronic inflammatory disease.2

The team at Evommune brings decades of combined knowledge, rising to meet this challenge head-on, across all stages of discovery and development. Their extensive R&D expertise in immunology, combined with first-hand experience shepherding novel agents through regulatory pathways, has already benefitted millions of patients.

1 “An Epidemic of Chronic Illness is Killing us Too Soon” Washington Post. October 3, 2023.
2 Pahwa R, Goyal A, Jialal I. Chronic Inflammation. StatPearls. Last Update August 7, 2023.

Our team is committed to making a difference for patients.